Finance

Lists
1177:HKG
Sino Biopharmaceutical Ltd
5,25 HK$
-0,38%
(-0,020) 1D
16 қаз., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1177...
Open
5,40 HK$
High
5,50 HK$
Low
5,14 HK$
Mkt. cap
98,09 млрд
Avg. vol.
69,33 млн
Volume
83,88 млн
Dividend
2,29%
Quarterly dividend
0,03 HK$
Ex-dividend date
2025 ж. 29 там.
P/E ratio
33,86
52-wk high
7,79 HK$
52-wk low
4,19 HK$
EPS
0,16 HK$
Shares outstanding
12,64 млрд
No. of employees
23 мың
Open
5,40 HK$
High
5,50 HK$
Low
5,14 HK$
Mkt. cap
98,09 млрд
Avg. vol.
69,33 млн
Volume
83,88 млн
Dividend
2,29%
Quarterly dividend
0,03 HK$
Ex-dividend date
2025 ж. 29 там.
P/E ratio
33,86
52-wk high
7,79 HK$
52-wk low
4,19 HK$
EPS
0,16 HK$
Shares outstanding
12,64 млрд
No. of employees
23 мың
News stories
From web sources and news partners
Profile
Sino Biopharmaceutical Limited, shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Ltd
CEOLi Yi
Employees22,8 мың
Founded2000
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
7,13 млрд
7,13 млрд
9,72 млрд
9,72 млрд
Cost of goods sold
1,31 млрд
1,31 млрд
1,65 млрд
1,65 млрд
Cost of revenue
1,31 млрд
1,31 млрд
1,65 млрд
1,65 млрд
Research and development expenses
2,93 млрд
2,93 млрд
1,54 млрд
1,54 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,80 млрд
2,80 млрд
3,11 млрд
3,11 млрд
Operating expense
4,38 млрд
4,38 млрд
4,77 млрд
4,77 млрд
Total operating expenses
5,69 млрд
5,69 млрд
6,42 млрд
6,42 млрд
Operating income
1,44 млрд
1,44 млрд
3,31 млрд
3,31 млрд
Other non operating income
97,99 млн
97,99 млн
76,64 млн
76,64 млн
EBT including unusual items
488,22 млн
488,22 млн
3,67 млрд
3,67 млрд
EBT excluding unusual items
1,55 млрд
1,55 млрд
3,56 млрд
3,56 млрд
Income tax expense
323,77 млн
323,77 млн
597,96 млн
597,96 млн
Effective tax rate
66,32%
66,32%
16,29%
16,29%
Other operating expenses
-1,35 млрд
-1,35 млрд
113,21 млн
113,21 млн
Net income
-522,62 млн
-522,62 млн
1,72 млрд
1,72 млрд
Net profit margin
-7,33%
-7,33%
17,66%
17,66%
Earnings per share
-
-
-
-
Interest and investment income
196,36 млн
196,36 млн
250,06 млн
250,06 млн
Interest expense
-77,56 млн
-77,56 млн
-84,75 млн
-84,75 млн
Net interest expenses
118,80 млн
118,80 млн
165,31 млн
165,31 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,66 млрд
1,66 млрд
3,57 млрд
3,57 млрд
Gain or loss from assets sale
-5,58 млн
-5,58 млн
-
-
AI content may include mistakes. Learn more
Google қолданбалары